G007-LK Tankyrase 1/2 Inhibitor: Precise Modulation of Wnt/β-Catenin Signaling

Executive Summary: G007-LK is a small-molecule inhibitor targeting tankyrase 1/2 (TNKS1/2) with high selectivity and nanomolar potency (IC₅₀ values: 46 nM for TNKS1, 25 nM for TNKS2) [APExBIO]. It effectively inhibits poly(ADP-ribosyl)ation, resulting in suppression of Wnt/β-catenin signaling and induction of β-catenin degradation [Jia et al., 2017]. In cellular models, G007-LK stabilizes AXIN1/2 and reduces cytosolic and nuclear β-catenin, leading to reduced tumor cell proliferation [Jia et al., 2017]. In vivo, it suppresses tumor growth in APC-mutant colorectal and hepatocellular carcinoma models [Jia et al., 2017]. G007-LK is recommended for research on Wnt/β-catenin signaling, APC mutation cancer biology, and Hippo-YAP pathway modulation.

Biological Rationale

Tankyrases (TNKS1 and TNKS2) are poly(ADP-ribose) polymerases involved in the regulation of Wnt/β-catenin signaling, telomere maintenance, and cell cycle progression [Jia et al., 2017]. Overactivation of tankyrases leads to hyperactivation of Wnt/β-catenin signaling, a hallmark in many cancers, especially those with APC mutations such as colorectal carcinoma [bi10773.com]. By targeting tankyrase activity, G007-LK provides a mechanism to selectively modulate these oncogenic pathways. This article extends the focus of prior summaries by detailing in vivo benchmarks and translational workflow guidance for G007-LK.

Mechanism of Action of G007-LK tankyrase 1/2 inhibitor

G007-LK binds to and inhibits the catalytic PARP domain of both TNKS1 and TNKS2, with IC₅₀s of 46 nM and 25 nM, respectively [APExBIO]. This inhibition prevents auto-poly(ADP-ribosyl)ation, blocking tankyrase-mediated degradation of AXIN1 and AXIN2. As a result, AXIN1/2 are stabilized, promoting assembly of the β-catenin destruction complex. This leads to increased ubiquitination and proteasomal degradation of β-catenin, reducing its cytosolic and nuclear levels [Jia et al., 2017]. In APC-mutant cell lines, such as SW480, G007-LK induces formation of dynamic degradasomes containing phosphorylated β-catenin, β-TrCP, and ubiquitin. Additionally, G007-LK modulates the Hippo pathway by stabilizing negative YAP regulators (AMOTL1/2), thereby reducing YAP activity [Jia et al., 2017].

Evidence & Benchmarks

• G007-LK inhibits auto-PARylation of TNKS1 (IC₅₀ = 46 nM) and TNKS2 (IC₅₀ = 25 nM) in enzymatic assays (APExBIO).
• In Wnt3a-stimulated HEK 293 cells, G007-LK inhibits ST-Luc Wnt reporter with an IC₅₀ of 0.05 μM (APExBIO).
• In APC-mutant SW480 colorectal cancer cells, G007-LK induces degradasome formation and reduces β-catenin protein levels (bi10773.com).
• In COLO-320DM xenograft mouse models, G007-LK reduces tumor burden and suppresses TNKS1/2 and β-catenin protein levels, while stabilizing AXIN1/2 (Jia et al., 2017).
• G007-LK decreases YAP protein levels and YAP target gene expression, upregulating AMOTL1/2 in hepatocellular carcinoma cell lines (Jia et al., 2017).
• Tankyrase inhibition with G007-LK synergizes with MEK/AKT inhibitors to further suppress HCC cell proliferation (Jia et al., 2017).

This article extends prior workflow-focused reviews such as Practical Advances in Wnt/β-Catenin Assays with G007-LK by providing direct links to controlled benchmark data and clarifying synergy with other pathway inhibitors.

Applications, Limits & Misconceptions

G007-LK is primarily used in research focused on Wnt/β-catenin signaling, APC-mutant colorectal cancer, and Hippo-YAP cross-talk studies. It serves as a precise tool for dissecting poly(ADP-ribosyl)ation-dependent mechanisms in cancer biology. Its validated use in hepatocellular carcinoma models further extends its utility to studies of Hippo pathway modulation [Jia et al., 2017]. For further detail on protocol integration, see G007-LK Tankyrase 1/2 Inhibitor: Precise Modulation of Wnt/β-Catenin, which this article updates by addressing recent in vivo synergy data and clarifying dose-response benchmarks.

Common Pitfalls or Misconceptions

• G007-LK is not a pan-PARP inhibitor: Its selectivity is restricted to tankyrase 1/2, with little activity against other PARP family members (APExBIO).
• Limited solubility in aqueous buffers: G007-LK is insoluble in water and ethanol; DMSO (≥26.5 mg/mL) is required for stock solutions (APExBIO).
• Not suitable for long-term solution storage: Prepare fresh aliquots due to solution instability; store solid at -20°C (APExBIO).
• Not a direct β-catenin inhibitor: Reduction in β-catenin is mediated via AXIN stabilization and the destruction complex, not by direct β-catenin binding (Jia et al., 2017).
• In vivo efficacy may depend on tumor genotype: Strongest effects are seen in APC-mutant or Wnt-driven tumors (Jia et al., 2017).

Workflow Integration & Parameters

G007-LK (SKU B5830, APExBIO) is supplied as a solid and should be stored at -20°C. For use, dissolve in DMSO to ≥26.5 mg/mL; warming to 37°C or using an ultrasonic bath may enhance solubility. Avoid aqueous or ethanol-based solvents. Do not store working solutions long-term. For cell-based assays, titrate from 10 nM to 1 μM depending on cell line and endpoint. In vivo, doses should be determined by pilot tolerability studies and referenced against published xenograft protocols [Jia et al., 2017]. For further scenario-driven guidance, see Practical Advances in Wnt/β-Catenin Assays with G007-LK, which this article extends by providing validated solution handling and stability notes.

Conclusion & Outlook

G007-LK is a validated, potent, and selective tankyrase 1/2 inhibitor for the targeted study of Wnt/β-catenin and Hippo-YAP signaling in cancer biology. Its nanomolar efficacy, robust benchmark data, and translational utility in APC-mutant and HCC models make it an indispensable tool for mechanistic and preclinical research [Jia et al., 2017]. For reproducible results and maximal pathway selectivity, strict adherence to storage and solubility parameters is essential. For more information or to purchase, visit the G007-LK tankyrase 1/2 inhibitor product page at APExBIO.